Last update March 24, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Etonogestrel is also known as
Etonogestrel in other languages or writings:
Etonogestrel belongs to this group or family:
Main tradenames from several countries containing Etonogestrel in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 325 | daltons |
Protein Binding | 96 - 99 | % |
VD | 3.1 | l/Kg |
Tmax | 200 | hours |
T½ | 25 | hours |
M/P ratio | 0.5 | - |
Theoretical Dose | 0.00003 | mg/Kg/d |
Relative Dose | 2.2 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Progestin, active metabolite of desogestrel. It is used as a progestogen-only contraceptive in the form of a subcutaneous implant for 3 years or associated with ethinylestradiol in the form of a vaginal ring 3 out of 4 weeks.
It is excreted in breast milk in negligible amount (Reinprayoon 2000) and no problems were observed in infants whose mothers used this medication. (Carmo 2017, Bahamondes 2013, Brito 2009, Taneepanichskul 2006)
Although it is considered safer to start using it after 4-6 postnatal weeks (Berens 2015), there have been studies that found that implants applied early in the first days or hours after birth does not affect either production or milk composition and growth of infants. (SMFM 2019, Carmo 2017, Lopez 2015, Braga 2015, Phillips 2015, WHO/OMS 2015, Mwalwanda 2013, CDC 2013, Gurtcheff 2011)
One in 100 women using etonogestrel implants may have a significant decrease in milk production, so it is advisable to monitor the growth of the infant. (Stuebe 2016)
During lactation progestin-only contraceptives are preferable to combined with estrogen and, in this case, those with a lower dose of estrogen. (CDC 2016, 2013 y 2010, WHO/OMS 2015, Altshuler 2015, Berens 2015, CLM 2012)
For the first 4-6 weeks postpartum, non-hormonal methods are the first choice, followed by IUDs and progestogen implants. (Berens 2015, Mwalwanda 2013, Rowe 2013, CLM 2012)
See below the information of this related product: